Mohammad Mahmoud, MD, shares his excitement looking forward to the presentation of 50 research papers focusing solely on metastatic and advanced prostate cancer. Notable studies include PROpel, which met primary endpoints by comparing olaparib plus abiraterone versus abiraterone alone, and investigations into PSMA-targeted therapies. Exciting prospects also include trials like ARV-766 Part C, combining PROTAC androgen receptor degrader with abiraterone, and studies on molecular targets or targeted therapies, such as hydrogel-encapsulated exosome vaccine immunotherapy and antibody-drug conjugates.
AUA 2024 offers valuable learning opportunities, including forums on advanced prostate cancer and instructional courses on the new AUA guidelines. In addition, new programs like P2s and Clinical Trials in Progress highlight groundbreaking research expected to shape clinical practice and benefit patients.
Medscape © 2024 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: AUA 2024: Anticipating Developments in Metastatic Prostate Cancer Research - Medscape - May 10, 2024.
Comments